Navigation Links
Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
Date:9/28/2007

EMERYVILLE, Calif., Sept. 28 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc., today announced that it received a staff determination letter on September 28, 2007 from the Listing Qualifications Department of The NASDAQ Stock Market indicating that the Company fails to comply with the market value of listed securities requirement for continued listing on the NASDAQ Capital Market, as set forth in NASDAQ Marketplace Rule 4310(c)(3)(B) and therefore that its securities are subject to potential delisting from the NASDAQ Capital Market. The Company has requested a hearing to appeal the Staff Determination. Delisting actions have been stayed pending the completion of the appeal, which is expected to be heard in 3 to 6 weeks. There can be no assurance that the hearing panel will grant the Company's request for continued listing.

The Company anticipates that it will regain compliance with this listing requirement if it is able to complete its planned public offering of up to $65 million of common stock, pursuant to a registration statement on Form S-1 filed with the SEC on August 13, 2007. This offering is expected to close in October 2007.

About Neurobiological Technologies, Inc.

NTI is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. The company is currently developing Viprinex (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke.

http://www.ntii.com

A registration statement relating to NTI's common stock has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. A copy of the preliminary prospectus relating to these securities may be obtained from Merriman Curhan Ford & Co. by calling 415-248-5600.


'/>"/>
SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... (PRWEB) , ... April 29, 2016 , ... Monthly subscription ... products on the market. They recently reviewed the ZEN BOX , the aromatherapy ... are two single essential oils (like lavender or frankincense) and one Zen Blend (like ...
(Date:4/28/2016)... ... April 28, 2016 , ... Sanford Health’s ... week. A group of researchers and leaders from Sanford Health were selected to ... and Its Cultural Impact ” and receive the 2016 Pontifical Key Innovation Award ...
(Date:4/28/2016)... ... 2016 , ... CastCoverz!, America’s #1 trusted brand for cast ... waterproof cast protector . As the largest one-stop, orthopedic shop, CastCoverz! offers ... night, weatherproof and waterproof covers for most orthopedic devices, including but not limited ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... announces today the open availability of a new CDISC standard, Clinical Trial ... registering clinical trials. This innovative standard will make it possible to build ...
(Date:4/28/2016)... ... April 28, 2016 , ... Trinity Health, one of ... leading force in the fight to reduce tobacco use and its deadly toll, ... help reduce tobacco use. The initiative brings together two organizations committed to achieving ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
(Date:4/27/2016)... 2016 At the Sachs CEO ... a Phase 2 clinical study of its lead drug ... cochlear implantation (CI) surgery. This large, placebo-controlled, double-blind, phase ... Germany and France . ... the time of surgery. "Despite advances in cochlear implant ...
(Date:4/26/2016)... 26, 2016 US demand for infection ... 4.9 percent annually to $27.6 billion in 2020.  ... to decrease rates of healthcare-associated infections (HAIs) will ... and services.  Although declining, the overall rate of ... levels set by the CDC.  Recent statistics indicate ...
Breaking Medicine Technology: